Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium.
Williams
Mark E
ME
Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA. mark.williams@joslin.harvard.edu
D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors* / Q000502:physiology; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D011733:Pyridoxamine / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; D011733:Pyridoxamine; C004479:pimagedine